BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Al-Dujaili AH, Mousa RF, Al-Hakeim HK, Maes M. High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments. Schizophr Bull 2021;47:530-41. [PMID: 32971537 DOI: 10.1093/schbul/sbaa136] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Ozdamar Unal G, Hekimler Ozturk K, Inci HE. Increased NLRP3 inflammasome expression in peripheral blood mononuclear cells of patients with schizophrenia: a case-control study. International Journal of Psychiatry in Clinical Practice. [DOI: 10.1080/13651501.2022.2106245] [Reference Citation Analysis]
2 Huang J, Tong J, Zhang P, Zhou Y, Li Y, Tan S, Wang Z, Yang F, Kochunov P, Chiappelli J, Tian B, Tian L, Elliot Hong L, Tan Y. Elevated salivary kynurenic acid levels related to enlarged choroid plexus and severity of clinical phenotypes in treatment-resistant schizophrenia. Brain, Behavior, and Immunity 2022. [DOI: 10.1016/j.bbi.2022.08.001] [Reference Citation Analysis]
3 Ma H, Cheng N, Zhang C. Schizophrenia and Alarmins. Medicina (Kaunas) 2022;58:694. [PMID: 35743957 DOI: 10.3390/medicina58060694] [Reference Citation Analysis]
4 Vallée A. Neuroinflammation in Schizophrenia: The Key Role of the WNT/β-Catenin Pathway. Int J Mol Sci 2022;23:2810. [PMID: 35269952 DOI: 10.3390/ijms23052810] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Maes M, Plaimas K, Suratanee A, Noto C, Kanchanatawan B. First Episode Psychosis and Schizophrenia Are Systemic Neuro-Immune Disorders Triggered by a Biotic Stimulus in Individuals with Reduced Immune Regulation and Neuroprotection. Cells 2021;10:2929. [PMID: 34831151 DOI: 10.3390/cells10112929] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
6 Boczek T, Mackiewicz J, Sobolczyk M, Wawrzyniak J, Lisek M, Ferenc B, Guo F, Zylinska L. The Role of G Protein-Coupled Receptors (GPCRs) and Calcium Signaling in Schizophrenia. Focus on GPCRs Activated by Neurotransmitters and Chemokines. Cells 2021;10:1228. [PMID: 34067760 DOI: 10.3390/cells10051228] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
7 Maes M, Kanchanatawan B. In (deficit) schizophrenia, a general cognitive decline partly mediates the effects of neuro-immune and neuro-oxidative toxicity on the symptomatome and quality of life. CNS Spectr 2021;:1-10. [PMID: 33843548 DOI: 10.1017/S1092852921000419] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ivanovska M, Abdi Z, Murdjeva M, Macedo D, Maes A, Maes M. CCL-11 or Eotaxin-1: An Immune Marker for Ageing and Accelerated Ageing in Neuro-Psychiatric Disorders. Pharmaceuticals (Basel) 2020;13:E230. [PMID: 32887304 DOI: 10.3390/ph13090230] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]